Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caredx Inc (CDNA)

Caredx Inc (CDNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,014,259
  • Shares Outstanding, K 51,433
  • Annual Sales, $ 333,790 K
  • Annual Income, $ 52,550 K
  • EBIT $ -46 M
  • EBITDA $ -26 M
  • 60-Month Beta 2.51
  • Price/Sales 3.19
  • Price/Cash Flow 15.13
  • Price/Book 3.40

Options Overview Details

View History
  • Implied Volatility 142.87% (-52.57%)
  • Historical Volatility 75.08%
  • IV Percentile 95%
  • IV Rank 62.99%
  • IV High 195.44% on 02/11/26
  • IV Low 53.41% on 05/21/25
  • Expected Move (DTE 8) 8.20 (42.95%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 8
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 1.15
  • Today's Open Interest 3,341
  • Open Int (30-Day) 3,302
  • Expected Range 10.90 to 27.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.00
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.01
  • Prior Year 1.51
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.24 +4.71%
on 02/05/26
21.49 -11.10%
on 01/22/26
-1.47 (-7.15%)
since 01/12/26
3-Month
15.15 +26.07%
on 11/17/25
21.49 -11.10%
on 01/22/26
+2.79 (+17.11%)
since 11/12/25
52-Week
10.96 +74.27%
on 07/17/25
25.55 -25.24%
on 02/18/25
-4.86 (-20.28%)
since 02/12/25

Most Recent Stories

More News
CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

AlloHeme Identified Cancer Relapse Earlier Than Standard Monitoring Methods in AML and MDS Patients Following Allogeneic HCT Ultra‑Sensitive, Non‑Invasive Surveillance...

CDNA : 19.10 (-3.14%)
CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare...

CDNA : 19.10 (-3.14%)
CareDx to Present AlloHemeâ„¢ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

Company to host investor webcast and conference call on February 12 at 7 a.m. PT / 10 a.m. ET Investor webcast will feature the clinical validation...

CDNA : 19.10 (-3.14%)
CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference 

CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value...

CDNA : 19.10 (-3.14%)
CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Expects Fourth Quarter Revenue Growth of Approximately 25% Year-Over-Year Expects Full Year 2025 Revenue of Approximately $380 Million

CDNA : 19.10 (-3.14%)
CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling

TXG : 17.51 (-8.56%)
CDNA : 19.10 (-3.14%)
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...

CDNA : 19.10 (-3.14%)
CareDx Provides Notice of Proposed Derivative Settlement

CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT N ...

CDNA : 19.10 (-3.14%)
SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

Third SHORE Publication Highlights HeartCare’s Role in Risk Stratification and Personalized Post-Transplant Care

CDNA : 19.10 (-3.14%)
CareDx to Participate in Upcoming Investor Conferences

CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare...

CDNA : 19.10 (-3.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of...

See More

Key Turning Points

3rd Resistance Point 21.47
2nd Resistance Point 20.88
1st Resistance Point 19.99
Last Price 19.10
1st Support Level 18.51
2nd Support Level 17.92
3rd Support Level 17.03

See More

52-Week High 25.55
Fibonacci 61.8% 19.98
Last Price 19.10
Fibonacci 50% 18.25
Fibonacci 38.2% 16.53
52-Week Low 10.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar